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Abstract
The measurement of circulating hormones by immunoassay remains a cornerstone in 
preclinical endocrine research. For scientists conducting and interpreting immunoassay 
measurements of rodent samples, the paramount aim usually is to obtain reliable 
and meaningful measurement data in order to draw conclusions on biological 
processes. However, the biological variability between samples is not the only 
variable affecting the readout of an immunoassay measurement and a considerable 
amount of unwanted or unintended variability can be quickly introduced during the 
pre-analytical and analytical phase. This review aims to increase the awareness for 
the factors ‘pre-analytical’ and ‘analytical’ variability particularly in the context of 
immunoassay measurement of circulating metabolic hormones in rodent samples. 
In addition, guidance is provided how to gain control over these variables and how 
to avoid common pitfalls associated with sample collection, processing, storage 
and measurement. Furthermore, recommendations are given on how to perform a 
basic validation of novel single and multiplex immunoassays for the measurement 
of metabolic hormones in rodents. Finally, practical examples from immunoassay 
measurements of plasma insulin in mice address the factors ‘sampling site and inhalation 
anesthesia’ as frequent sources of introducing an unwanted variability during the pre-
analytical phase. The knowledge about the influence of both types of variability on the 
immunoassay measurement of circulating hormones as well as strategies to control these 
variables are crucial, on the one hand, for planning and realization of metabolic rodent 
studies and, on the other hand, for the generation and interpretation of meaningful 
immunoassay data from rodent samples.
Introduction
After the discovery, in 1959, of the radioimmunoassay 
which enabled the measurement of insulin in human 
plasma (1), circulating metabolic hormones such as 
insulin (2) or growth hormone (3, 4) were quickly 
investigated for research purposes in laboratory rodents. 
The replacement of radioactivity by an enzymatic 
label in 1971 by Engvall and Perlmann (ELISA) (5) as 
well as by van Weemen and Schuurs (EIA) (6), and the 
associated increased handling convenience led to a 
boost in using immunoassays and ever since they have 
arrived as standard tools in science. Today, the analysis 
of metabolic hormones by immunoassay is an essential 
diagnostic tool in medicine. In parallel, immunoassay 
measurements of circulating parameters have been crucial 
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for an overwhelming number of scientific discoveries 
in metabolic diseases. When measuring hormones in 
laboratory rodents, the paramount aim usually is to 
generate scientific data rather than to acquire diagnostic 
information. Especially after the identification of a novel 
circulating hormone or after the recognition of novel 
functions of a previously known parameter, the interest 
to measure this specific parameter in the circulation of 
rodents may arise or may experience a revival among 
a broader scientific community. Immunoassays are 
particularly suitable to serve this demand for a number 
of reasons. If appropriate antibodies reliably recognizing 
the antigen of interest are available, larger batches of 
immunoassays are relatively easy to produce in a short 
amount of time. In addition, the technical procedures to 
conduct immunoassays are established in most research 
labs and many groups have access to the required 
analytical equipment. It is important to distinguish 
between immunoassays installed for diagnostic purposes 
in humans and immunoassays used to detect circulating 
metabolic parameters in rodents for research purposes. 
The immunoassay classification ‘for research purposes 
only’ allows assay manufacturers to quickly provide the 
necessary tools to the research community without the 
need for exhaustive assay validation processes, which 
are typically required for diagnostic assays in human 
medicine. At the same time, the lack of thorough 
validation processes for novel immunoassays due to the 
need for timely solutions also comes with an important 
limitation: the quality of ‘research immunoassays’ is often 
worse compared to immunoassays used in diagnostic 
laboratory medicine. This topic has also recently been 
highlighted in an editorial discussing immunoassays for 
the measurement of (rodent) steroid hormones (7). It has 
perspicaciously been warned that using commercially 
available rodent immunoassays without implementing 
the traditional controls, such as spiked samples, mixing 
experiments and serial dilutions can seriously impact 
the quality of research data. The author also raised the 
awareness that self-generated data from specific samples 
used in the experiments should be used to describe the 
performance of an immunoassay rather than reporting 
performance characteristics provided by the manufacturer 
in the ‘instructions for use’ (IFU) (7).
The primary aim of this review is to bring this issue 
to the attention of researches with the goal to also 
provide some guidance on how to avoid common pitfalls. 
Furthermore, recommendations are given how to perform 
a basic validation of novel immunoassays for measurement 
of metabolic hormones in rodents. Finally, practical 
measurement examples should increase the awareness for 
the potential introduction of unwanted variability during 
the pre-analytical and the analytical phases.
Sources of variability in immunoassays
By nature, every analytical method is subject to 
variability. In addition to the biological variability usually 
being the desired readout of immunoassay analyses in 
research, pre-analytical and analytical variability also 
affect the measurement readout in immunoassays. Pre-
analytical and analytical variability in this context 
relate to the phenomenon that measurement readouts 
in immunoassay always need to be regarded as relative 
analyte concentrations (mostly relative to a calibrator 
curve) and thus the term ‘variability’ seeks to describe 
the difference between the true analyte concentration 
in the sample and the observed measurement result 
(8, 9). Both types of variability are typically less well 
controlled and studied in research immunoassays used 
for measurement of metabolic hormones in rodents 
compared to established immunoassays used in routine 
laboratory diagnostics. Pre-analytical variability describes 
the variability potentially introduced by differences 
related to sample collection, sample preparation and 
processing as well as sample storage (9, 10, 11, 12, 13). In 
contrast, analytical variability summarizes the variability 
introduced into a measurement result by factors that are 
directly connected to the analytical method, such as the 
choice and specificity of antibodies, assay buffers, assay 
design (sandwich vs competitive), matrix differences 
between calibrators and samples, incubation times or 
interference with other endogenous ligands (8, 9, 14, 15). 
Pre-analytical variability sometimes is regarded to be of 
minor importance. However, it has been estimated that 
the variability introduced during this phase accounts 
for up to 93% of the total errors encountered within the 
entire diagnostic process in human laboratory medicine 
(12). Considering that the pre-analytical phase in 
human medicine – despite well-known shortcomings – 
already has a high degree of standardization, it must be 
assumed that in the less well-controlled and standardized 
environment of many rodent studies the factor ‘pre-
analytical variability’ might even more severely affect 
sample quality.
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Blood sampling site and effect of 
isoflurane anesthesia
One aspect that is relatively well known and described 
within the perimeter ‘pre-analytical and unwanted 
biological variability’ is that – depending on the analyte 
– a considerable amount of variability can potentially be 
introduced by the choice of the blood sampling method 
and site. Most available data and recommendations have 
been reported for humans and domestic animals (e.g. (16, 
17, 18, 19, 20)), with significantly less data reported for 
rodents, particularly with respect to potential effects on 
circulating endocrine parameters. Not surprisingly, also in 
rodents the blood sampling site can affect measurement 
results. In this context, a solid amount of data has been 
reported for rodents showing that the blood sampling 
site and technique has a significant impact upon the 
measurement of many clinical chemistry parameters 
including hematopoietic cells, plasma glucose, liver lipids 
and enzymes and the presence of clots or hemolysis (21, 
22, 23). For example, Hoggatt et  al. have demonstrated 
in mice that sampling from central sites yields lower 
numbers of red and white blood cells compared with 
blood sampled peripherally (23). Schnell and colleagues 
also showed in mice that the site of blood collection 
plays a substantial role for measurement of many clinical 
chemistry parameters such as transaminases or lipases (24). 
Similarly, Fernández et al. found significant differences in 
8 out of the 9 biochemical parameters studied (including 
transaminases, albumin, triglycerides, total cholesterol and 
creatinine) between submandibular vein and retrobulbar 
plexus blood collection in C57BL/6J mice (25). This type 
of systematic analysis is less often conducted in rodent 
studies and data are usually only reported for individual 
hormones. Among the reported hormones, particular 
attention has been given to hormones belonging to the 
hypothalamic-pituitary-adrenal (HPA) axis as well as to 
adrenal medullary hormones (26, 27, 28, 29, 30).
As another example of a frequently measured 
metabolic parameter in rodents, we here depict that 
the sampling site can affect the measurement results 
of plasma insulin in mice. Insulin concentrations were 
measured in samples collected either via puncture of the 
tail vein or from the retrobulbar sinus of adult C57BL/6J 
mice. During the whole sampling process, mice remained 
under isoflurane narcosis and the two blood samples were 
collected within 3 min per mouse into prefilled EDTA 
tubes on ice. Further details on sampling and analytical 
procedures can be found in the ‘Materials and methods’ 
section. In another cohort of 20 mice, we studied the 
effect of isoflurane narcosis on plasma insulin. Therefore, 
two blood samples were collected from the tail vein of 
the same mouse, one time under isoflurane narcosis in 
an inhalation chamber or for the subsequent sampling 
without anesthesia in conscious mice. Figure 1A shows that 
the measured plasma insulin concentrations are clearly 
lower in all five mice when blood was collected from the 
retrobulbar sinus. In contrast (and as expected), repeated 
sampling from the same sampling site within a short time 
frame did not significantly affect the measured analyte 
concentration (Fig.  1B). This small set of data does not 
claim to be a representative measure for the effect of the 
sampling site on plasma insulin measurements. Instead, 
it is intended to illustrate how quickly the alternation of 
the sampling site can lead to a high degree of unwanted 
variability in measured analyte concentrations in rodents. 
Thus, to avoid a potential bias in measurement results of 
rodent metabolic hormones within one experiment, it is 
very important to stay consistent with the blood sampling 
site, especially when comparing two or more experimental 
groups such as ‘compound treatment’ vs ‘vehicle 
treatment’ or when comparing measurement results from 
repeated blood samplings. Furthermore, the procedure 
of blood sampling should be precisely documented to 
Figure 1
Example illustrating the effect of alternating the blood sampling site 
within short intervals (tail vein puncture vs retrobulbar sinus) on 
measured plasma insulin concentrations in five anesthetized C57BL/6J 
mice (A). Blood sampling sites were alternated from mouse to mouse to 
avoid the introduction of a systematic error. (B) Shows the expected 
absence of effects on measured plasma insulin concentrations in another 
cohort of anesthetized C57BL/6J mice when blood was sampled within 
short intervals from the same site (in this case from the retrobulbar sinus).
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help with the interpretation of measurement data also at 
potentially much later points in time.
Unwanted variability during the blood sampling 
process may also be introduced by comparing analyte 
concentrations in samples that have been collected 
under narcosis with analyte concentrations in samples 
that have been collected without prior narcosis. It is well 
documented that anesthetics are capable to influence 
intestinal motility, gastric emptying and glucose 
metabolism (31, 32, 33). In our hands and using a 
small set of samples collected from the tail vein with or 
without isoflurane anesthesia in C57BL/6J mice, plasma 
insulin concentrations were significantly (P < 0.05) lower 
when blood was collected under isoflurane anesthesia. 
Nevertheless, plasma insulin concentrations measured 
in samples collected with the two different anesthesia 
protocols showed a tight and significant correlation 
(Fig. 2). The displayed data show an inhibitory effect of 
isoflurane narcosis on plasma insulin secretion, which 
is in accordance with the majority of published studies 
(32, 33, 34, 35, 36, 37, 38). Interestingly, Zardooz et  al. 
described in male rats that the effect of isoflurane exposure 
on plasma insulin concentrations seems to depend on 
the fasting state, as they could not detect effects of the 
isoflurane anesthesia on plasma insulin in the fed state 
(39). The effect of isoflurane narcosis on plasma insulin has 
been found to be even more pronounced when glucose-
stimulated insulin concentrations are measured, e.g. as 
usually done during an oral glucose tolerance test. This 
effect is probably best explained by the inhibitory effect 
of isoflurane on gastric emptying and intestinal motility, 
thus affecting the passage time of the orally administered 
glucose (33, 35, 36).
In contrast to the parameter ‘rodent insulin’, where 
already several groups reported clear effects of the narcosis 
protocol on the circulating concentrations, many other 
metabolic hormones in rodents unfortunately lack this 
type of systematic studies. It may be assumed that the 
type of narcosis and the sampling site can affect the 
measurement result of many other metabolic hormones. 
However, there are also examples from relatively stable 
circulating parameters in rodents, such as IGF-I, which 
seems to be only marginally affected by these variables 
((40) and unpublished observations). Unfortunately, there 
is no strict rule that can predict if or in which direction 
a specific narcosis protocol or sampling site affects the 
analyte of interest. The easiest and best way to circumvent 
this potential source of unwanted biological variability in 
rodent studies is to stick exactly to the same sampling 
procedures, including the usage of the same equipment 
(e.g. blood sampling devices) needed to collect the sample, 
as well as to only compare samples from animals that 
underwent identical pre-treatment procedures. Of course, 
easily controllable biological variables such as the fasting 
condition before sampling, e.g. during dynamic tolerance 
tests, should be kept constant between experimental 
groups throughout the enite study. Further guidance 
and recommendations on this topic can also be found in 
recent comprehensive literature reports (41, 42).
Sample processing
After sample collection, the ‘pre-analytical pitfall journey’ 
continues. Blood samples should be collected in suitable 
containers to obtain plain serum or alternatively in 
containers pre-filled with anti-coagulants such as EDTA, 
sodium citrate or heparin to obtain plasma. Many sources 
recommend the usage of either serum or heparin- or 
EDTA-plasma for routine biochemistry analyses (16, 43), 
which – in principle – are also both appropriate for most of 
the analyses of metabolic hormones in rodents. However, 
there are several analytes where serum or plasma should be 
preferred. For example, it has been reported that bile acids 
concentrations are about 60% lower when measured in 
Figure 2
Comparison of measured plasma insulin concentrations in samples 
collected from the tail vein with or without prior isoflurane anesthesia in 
C57BL/6J mice. The anesthetic procedure before blood sampling was 
alternated from mouse to mouse to avoid the introduction of a 
systematic error. In this example, measured plasma insulin concentrations 
were significantly (P < 0.05) lower when blood was collected under 
isoflurane anesthesia but showed a tight and significant non-parametric 
correlation.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-18-0035
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 11/29/2019 10:01:38AM
via free access
M Bielohuby et al. Hormone measurement 
variability in rodents
R1517:4
heparin-plasma compared to serum (44). Trace elements 
like Zn or Mg can only be analyzed in serum, because 
in plasma, the ions form complexes with the chelating 
agents such as EDTA or heparin due to their bivalent 
nature (45). In contrast, some peptide hormones like the 
pituitary-derived ACTH should be measured in plasma for 
stability reasons (46).
It may also be useful to add an unspecific protease 
inhibitor to the blood sample or to pre-load the sample 
collection tube with such an inhibitor. This can be 
recommended particularly if the complete list of analytes 
is not yet specified at the time of sampling or if it is already 
known that analytes are susceptible to degradation by 
proteases (e.g. active GLP-1). Furthermore, it is important 
to check if further ‘additives’ are required to stabilize 
the analyte. One example for an analyte requiring a 
specific sampling protocol is acylated ghrelin, because 
here, acidification of the sample through addition of 
HCl is required to preserve the octanoyl group of ghrelin 
(47, 48). Depending on the number and stability of 
the analytes of interest, it might be required to collect 
several aliquots with different additives to obtain the 
optimal sample type for each analyte. Unfortunately, 
such an approach is often not possible in rodent 
studies because of the limitations in sampling volume. 
However, since the type of matrix as well as the sample 
pre-treatment conditions can have a significant impact 
on the immunoassay measurement result, a minimum 
requirement is that only data from samples which were 
collected and processed with the same pre-treatment 
protocols should be compared.
In previous experiments in rats (9), we have 
demonstrated that the centrifugation protocol had only 
limited or no effect on the measurement results of five 
different metabolic hormones, including insulin and 
GLP-1. However, the lack of effects of the centrifugation 
protocol on these randomly selected hormones should 
not to be taken as a generalized rule for all metabolic 
hormones in each rodent species. Again, most important 
is consistency in all pre-analytical procedures throughout 
one set of experiments. After centrifugation, serum or 
plasma samples must be stored in appropriate tubes (not 
to forget a clear and wash-off resistant sample identifier) 
with appropriate lids (proper sealing of the tubes can 
prevent evaporation/contamination of the sample). If 
immunoassay measurements cannot be done right away, 
(long-term) storage should be carried out in the freezer, 
ideally at −70°C or lower, again to prevent proteolytic 
activity and sample evaporation. Frequent freeze-thaw 
cycles can also seriously affect analyte concentrations (9) 
and thus should be avoided. If multiple analytes are to be 
measured using singleplex assays, it is advisable to prepare 
multiple aliquots of the sample.
Realizing the many steps that are necessary to obtain 
the final matrix in which the analyte of interest will be 
measured, it appears obvious that these steps can vary 
between different research groups and labs. Luckily, 
the many different possibilities of sample collection, 
processing and storage are not a too serious issue in 
preclinical rodent research as long as conditions are kept 
standardized and consistent within an experimental 
series and as long as all samples undergo exactly the same 
procedures before measurement. It is appeasing to realize 
that any potential measurement variability introduced 
by one or multiple specific pre-analytical procedure(s) 
can be considered to be of minor relevance in this 
context because this ‘bias’ should – in theory – affect the 
measurement results of all samples in the same direction 
and in a similar order of magnitude. Overall, the relative 
differences (or lack of differences) between control and 
observer groups within one experiment should remain 
constant if the above described general rules are applied. 
Nevertheless, it is very important to keep in mind that 
the pre-analytical phase has a significant impact on 
immunoassay measurements of rodent samples, also in 
order to avoid an unintended mixture of pre-analytical 
procedures between samples from the same experimental 
run. Of note, it is also likely that the selection of specific 
procedures during the pre-analytical phase contributes 
to differences in reported concentrations for the 
same hormones analyzed by different groups or by 
different labs.
Analytical variability
Knowledge about the existence of analytical variability and 
a basic understanding of how to control this variable is of 
great importance to conduct meaningful interpretations 
of measured values from rodent samples. However, 
a comprehensive discussion of the complex topics 
‘analytical variability’ and ‘measurement uncertainty’ 
in immunoassay measurements is beyond the scope of 
this review, and readers may be referred to more detailed 
literature for further insights (49, 50, 51, 52). Instead, the 
following section will summarize some considerations, 
which are of importance in the context of immunoassay 
measurement of metabolic hormones in rodents.
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Intra- and inter-assay variability in 
rodent immunoassays
Although the quality criteria for immunoassays used ‘for 
research purposes only’ (RUO) obviously can be less strict 
compared to immunoassays used for clinical diagnostics 
in human, also immunoassays used for the measurement 
of metabolic hormones in rodents should – in principle 
– follow the same guidelines and recommendations. 
Among others, the Clinical and Laboratory Standards 
Institute published recommendations with respect 
to acceptable limits of detection and quantification, 
imprecision, linearity and recovery (53, 54). The 
chosen analytical method (e.g. mass spectrometry or 
immunoassay) can significantly affect the measurement 
result, but also different types of the same method, 
e.g. sandwich-type or competitive immunoassays or 
assays from different manufacturers for the same analyte, 
likely will result in differences of reported absolute 
concentrations. Lack of standardization or harmonization 
has been recognized as one of the most relevant issues in 
diagnostic procedures used in clinical medicine. However, 
the lack of standardization is even more common in the 
less regulated market of RUO reagents. For example, we 
recently have shown considerable differences in assay 
readouts when IGF-I was measured in serum of mice with 
two different mouse-specific IGF-I immunoassays (9). 
Similar examples of a significant variability for the same 
analyte between rodent assays from different vendors are 
documented throughout literature. For the purpose of this 
review, and using the analysis of FGF-15 in mice as one 
example, here we illustrate the significant performance 
differences between immunoassays of different vendors 
(Table 1). To overcome such discrepancies for assays used 
in clinical diagnostics in humans, standardizing and 
harmonizing the preparations of the reference materials, 
using a single, recombinant calibrator for all assays of 
a specific analyte and reporting in the same mass units 
for each analyte have been recommended (55, 56). 
The shortcomings, but sometimes also the success of such 
efforts to standardize or harmonize assays in clinical labs 
is reflected by the results from external quality assessment 
schemes (EQAS), in which to participate is mandatory 
for clinical laboratories in most countries. This type of 
external quality control, however, is rarely performed for 
rodent research immunoassays. Luckily, the quantitative 
differences between assays from different manufacturers 
are of limited importance in most basic rodent studies 
as long as all samples from an experimental series have 
been measured in the same batch of immunoassays from 
the same provider – ideally in the same analytical run. 
In contrast to human diagnostics, where the measured 
concentration of an analyte is often interpreted in 
relation to absolute cut-off values or to analyte-specific 
age- and sex-matched reference intervals (and thus 
directly contributes to the clinical interpretation of a 
patient’s disease state), researchers investigating metabolic 
hormones in rodents are usually more interested to 
obtain the ‘relative changes’ of the analyte. ‘Relative’ 
in this context means that differences in measured 
concentrations are compared between an observer group 
and the corresponding control group. However, as soon 
as the analytical method to measure rodent hormones in 
a laboratory is being changed or data from one lab are 
being compared to those obtained in another lab using 
a different kit, the methodological differences leading to 
differences in absolute concentrations reported need to be 
taken into account.
In addition to the above-mentioned ‘between-assay 
variability’ – which is attributable to differences in the 
assay components provided by the manufacturer and 
completely independent from the operator using the 
assay – systematic and random errors in the actual lab 
work can also contribute to ‘between-assay variability’, 
but also to ‘within-assay’ variability. Such variability 
is an inherent feature of any analytical procedure and 
relates to random variability or systematic mistakes in an 
operators performance of the assay, but also to variability 
Table 1 Displays some basic performance characteristics of an exemplary assay comparison between immunoassays from two 
commercial vendors, both measuring FGF-15 in mouse plasma.
Vendor A Vendor B
Precision (intra-assay CV) (%) 14.7 4.1
Recovery at a concentration range in the lower third of the calibration curve (%) 380 60
Recovery at a concentration range in the middle third of the calibration curve (%) 260 58
Recovery at a concentration range in the upper third of the calibration curve (%) n.d. 54
Intra-assay variability was determined by 6-fold analysis, recovery was analyzed as ‘expected over observed’ concentrations using recombinant mouse 
FGF-15 from an external provider. Analytes were added at the low, medium and upper end of the calibration curve.
n.d.: not determined.
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in environmental conditions like temperature, humidity 
as well as in the technical performance of instruments like 
pipettes, plate shakers or washers. This inherent variability 
is often summarized as ‘coefficient of variability’ (% CV) 
or ‘measurement uncertainty’. Within one immunoassay 
run, such variability can be controlled by measuring all 
samples in duplicate or triplicate, a measure which – 
although expensive – should also be applied to rodent 
samples. Although the maximum acceptable degree of 
variability depends on the specific analyte and the specific 
research question, it is a common recommendation that 
the CV% for a duplicate analysis should not exceed 
15% otherwise the measurement should be repeated. 
In case the available sample volume is too low, and 
provided that the immunoassay for the desired analyte 
is sensitive enough, one might consider diluting the 
sample with a suitable diluent in order to achieve 
duplicate measurements or to repeat the measurement. 
The impact of environmental conditions is much harder 
to predict and to control. However, it is recommended 
to monitor and document some of the basic conditions 
during an assay run to allow retrospective identification 
of factors negatively affecting assay performance. In the 
clinical laboratory, the concept of internal quality control 
samples analyzed with each assay has been implemented 
to control between-assay variability. Manufacturers of 
rodent assays sometimes provide such control samples. 
However, it should be carefully examined by each user 
of the assay if these quality control samples are suitable 
to monitor assay performance in a concentration range, 
which is meaningful to the outcome of a rodent study. 
Most assays perform comparably well in the mid-range 
of the calibration curve, while the performance is less 
reliable toward the lower or upper end of the standard 
curve concentration ranges, which might be very relevant 
for a scientific conclusion from an experiment. It should 
also be checked whether the quality control material 
provided with an assay mirrors ‘real samples’ in terms 
of matrix. It is common that so-called ‘control samples’ 
just are made of one of the calibrators. It depends on the 
matrix of the real samples whether such an approach 
is sufficient to monitor assay quality. To control assay 
performance over a larger series of immunoassay plates 
it might be advisable to have your own ‘control sample’ 
running with each assay. Such samples can be produced 
from leftovers samples from previous experiments and 
should be separated into a sufficient number of aliquots to 
allow measuring one of the ‘real samples’ with each assay. 
This allows calculation of the CV% over the measurement 
series, thereby giving an estimate of the uncertainty 
associated with the generation of the data.
Basic assay validation steps for 
rodent immunoassays
It is fascinating to realize that nature has implemented 
such a complex set of regulatory factors controlling 
metabolism and new, previously unknown circulating 
metabolic hormones are discovered in periodic intervals. 
In addition, known hormones can also become a 
‘hot-topic’ with the need to develop novel or more 
sensitive immunoassays if research reveals a previously 
unrecognized (maybe broader) impact of this specific 
hormone in other relevant scientific areas such as 
metabolic research. Examples for recently discovered or 
recognized metabolic hormones include Asprosin, the 
glycoprotein CHI3L1 (chitinase-3-like protein 1), GDF15, 
Phoenixin or members of the fibroblast growth factor 
family (57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69). 
In order to also offer the required research tools, providers 
sell analyte-specific immunoassays for rodents usually 
soon after the sequence/structure of the new hormone has 
become available or if a relevant sales market is expected. 
It is sometimes surprising to see how quickly after the 
discovery process particularly smaller biotech companies 
manage to offer immunoassays for the new analytes.
As mentioned earlier, FGF-15 is an example of a 
metabolic hormone that has emerged as a new, potentially 
interesting factor controlling body weight and glucose 
metabolism. Here, assay performance data of two mouse-
specific FGF-15 immunoassays from two different vendors 
are displayed for the parameters ‘precision’, ‘recovery’ 
and ‘linearity’. Of note, the assay manufacturers/
vendors of these two mouse FGF-15 immunoassays are 
intentionally not named as this example is meant to 
increase the awareness for analytical differences between 
immunoassays from different sources rather than to 
provide recommendations for a specific mouse FGF-15 
immunoassay. Table 1 illustrates for this exemplary assay 
comparison that the robustness of measurement results 
as well as the overall assay performance clearly depends 
on the chosen immunoassay and obviously, both assays 
could be further optimized. The idea of conducting this 
type of basic assay validation is to provide guidance in 
case a researcher needs to opt between two (or more) 
available immunoassay options for a specific analyte. 
Furthermore, such a basic assay validation will also yield 
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-18-0035
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 11/29/2019 10:01:38AM
via free access
M Bielohuby et al. Hormone measurement 
variability in rodents
R1547:4
important data to decide if the chosen, newly established 
immunoassay is capable to deliver robust and meaningful 
data. Important steps of this basic validation include 
the analysis of precision and linearity; the latter can for 
example be done with serial dilutions of the calibrators or 
positive controls, which should always be delivered with 
an immunoassay kit. Other recent examples of hormone-
specific and extended, state-of-the-art assay validation 
efforts for novel immunoassays measuring hormones 
in samples from laboratory animal species can be found 
in the cited references (70, 71, 72, 73, 74). In addition, 
literature research or personal exchange during scientific 
meetings can be helpful to elucidate if other research 
groups have successfully used the (potentially novel) 
immunoassay to measure the analyte. In conclusion, 
before using a rodent immunoassay for the first time, 
it is highly recommended to invest time to check if 
others have effectively used a specific immunoassay for 
measurement of rodent samples and to include basic 
validation measurements, especially if the samples of 
interest are precious with only little available sample 
volumes. Ultimately, researchers understandably want 
to base their conclusions on meaningful measurement 
results aiming to avoid the generation of random numbers 
from precious rodent samples. In case the validation 
of a novel immunoassay is not successful or if data are 
not convincing, one may consider using alternative 
approaches for the measurement of the newly discovery 
hormone (e.g. LC–MS/MS).
Multiplexed immunoassays
A remarkable trend in preclinical research involving 
measurement of rodent metabolic hormones is the use 
of so-called multiplex(-ed) assays. These assays are based 
on a fascinating technology offering the potential to 
measure multiple, up to 100 analytes (75) in a single 
sample, which typically needs less than 100 µL of sample 
volume. This technique has many advantages including 
the increased efficiency at a reduced expense, greater 
output per sample/volume ratio and a higher sample 
throughput (76, 77).
On the contrary, this technical approach also warrants 
some caution and comes with challenges. Cross-reactivity 
and the probability of cross-talking interferences of assay 
components, which is increasing exponentially with 
the number of analytes in a multiplex immunoassay 
(78), have been difficult to mitigate, limiting the assay 
performance, and thus potentially returning inaccurate 
or even false results (79). Also in human diagnostics, 
technical and operational challenges are limiting the 
routine implementation of multiplexed assays in clinical 
settings (80). The challenges of this technology may 
be exemplified with the fact that all analytes are being 
measured in the same matrix. However, the manufacturers 
of multiplex technology assays, especially for rodent 
panels, rarely provide data on how different matrix 
types affect the measurement of single analytes in their 
multiplex panels and assume that ‘one matrix fits all’. 
As mentioned earlier, ACTH is an example of a hormone 
for which immunoassay measurements in plasma are 
recommended. However, rodent-specific multiplexed 
panels for hormones, including ACTH, are offered, 
which are described to also reliably function in serum 
(81). Similar to singleplex immunoassays, users of rodent 
multiplex immunoassays should carefully evaluate if the 
sample matrix has an effect on the analyte measurement. 
Overall, the same principles used for validation of single-
plexed immunoassays also apply to this technology and a 
basic validation should be carried out rigorously for each 
analyte in a new multiplex panel (80), e.g. as conducted 
by Sun et  al. for the simultaneous measurement of 
aldosterone and testosterone in mice (73). In case that 
the multiplex panel is pre-designed, one may use the own 
validation data to decide if all analytes or only a subset of 
analytes can be regarded to deliver reliable data.
With respect to analytical variability Figure 3 depicts 
(using murine plasma insulin measurements as an 
example) how different the measured concentrations 
between multiplex and singleplex immunoassays can 
be. Both, Passing-Bablok regression and Bland-Altman 
plot show, not surprisingly, that the overall correlation 
is relatively weak with a comparably high fit difference. 
Importantly, from this analysis, one cannot determine 
which measurement is ‘right’ or provides the ‘true’ value in 
plasma, because immunoassay measurements always need 
to be interpreted relative to a calibration curve and do not 
represent an absolute quantification. However, from this 
example, three important conclusions can be drawn with 
respect to using multiplex assays: (i) measurement results 
can differ between multiplex and singleplex assays and 
neither data from multiplex nor singleplex measurements 
should be regarded as the ‘true’ concentrations; (ii) data 
should always be compared and interpreted relative 
to biological controls (e.g. ‘no treatment’ or ‘wild-type’ 
controls) measured by the same assay method and ideally 
also in the same experimental run; (iii) during a series 
of experiments, it is mandatory to stick to the same 
measurement method and assay throughout.
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Concluding recommendations
In summary, it is obvious that pre-analytical and 
analytical variability can significantly affect the reliability 
and reproducibility of data on metabolic hormones 
in rodents. In view of the innumerable spectrum of 
commercially available assays for the measurement of 
hormones in rodents, it is very important to bear in mind 
that the market for the ‘research-use-only’ reagents is far 
less strictly regulated and standardized than the market 
for assays used in clinical diagnostics in humans. Most 
of the validation of these analytical methods remains to 
be done by the customer, i.e., the research lab using the 
assays. Having this awareness at the back of one’s mind 
is the first crucial step for appropriate planning, and also 
for interpretation of metabolic studies in rodent. Notably, 
measures exist to control variability and to avoid frequent 
pitfalls, and such measures need to be implemented in 
an attempt to obtain high-quality data. With respect to 
pre-analytical variability, it is of utmost importance that 
all samples undergo the same standardized workflows 
including a careful documentation of the relevant pre-
analytical steps. With respect to analytical variability, 
concerns have been expressed that current research 
immunoassays could have been pushed beyond their 
limits. Therefore, it is a challenge for both, assay providers 
and customers, to rapidly find a ‘balanced, equitable 
and scientifically sound solution’ (7) to improve the 
performance of immunoassay measurements in endocrine 
research involving rodent species. In the lab, one should 
clearly consider conducting a basic validation of an 
immunoassay with leftover samples before using it for the 
first time with precious samples. As for the pre-analytical 
period, also during the analytical process, all steps should 
follow a standardized procedure to minimize analytical 
variability. In case the basic immunoassay validation 
experiments do not provide the expected confidence in 
the method, contacting manufacturers or experienced 
colleagues may be helpful to discriminate between 
problems associated with the analytical method itself on 
the one hand and random errors in the performance of the 
assay on the other. Adherence to these recommendations 
will help to obtain reliable and meaningful data from 
measurements in rodent samples, ultimately reducing 
unpleasant surprises, resources and frustration.
Materials and methods
Analytical procedures related to the measurement 
of metabolic parameters in mice
Blood samples were collected from adult male and female 
C57BL/6J mice (Charles River). Mice were group-housed 
at room temperature in an environmentally controlled 
SPF-animal facility with a 12-h light-darkness cycle and 
had access to a standard maintenance rodent diet (Ssniff, 
Soest, Germany) and filtered tap water ad libitum. All 
animal experimental procedures were approved by the 
internal animal welfare committee as well as by German 
Figure 3
Plasma insulin was measured in the same 38 mouse samples by two 
different immunoassays (multiplex and singleplex). Measured 
concentrations showed a significant variability depending on the 
immunoassay. (A) Depicts the results using a Passing-Bablok regression 
and (B) shows the corresponding Bland-Altman plot for this assay 
comparison.
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government authorities. Table 1 displays basic performance 
characteristics of an exemplary assay comparison 
between immunoassays from two commercial vendors, 
both commercialized for the measurement of FGF-15 in 
mouse serum. Intra-assay variability was determined by 
6-fold analysis of mouse serum samples, and linearity 
was analyzed by measuring FGF-15 in serial dilutions of 
pooled mouse serum samples (using the diluent provided 
by the assay vendors). Recovery was analyzed as ‘expected 
over observed’ concentrations using recombinant mouse 
FGF-15 (% recovery = observed concentration/expected 
concentration × 100%). Analytes were added at the low, 
medium and upper end of the calibration curve. For the 
experiments related to different blood sampling sites, 
plasma insulin concentrations were measured in samples 
collected either via puncture of the tail vein or from the 
retrobulbar sinus of mice. During the whole sampling 
process, mice remained under isoflurane narcosis and the 
two blood samples were collected within 3 min per mouse. 
The ‘first/starting’ sampling site was alternated after each 
mouse to avoid the introduction of a timely bias. In another 
cohort of 20 mice, the effect of isoflurane narcosis on plasma 
insulin was studied. Therefore, two blood samples were 
collected from the tail vein of the same mouse, one time 
under isoflurane narcosis in an inhalation chamber or for 
the subsequent sampling without anesthesia in conscious 
mice (again alternating the timing of the procedure from 
mouse to mouse). All blood samples were collected with 
plastic capillaries coated with sodium heparin (SC-Sanguis 
Counting GmbH, Nümbrecht, Germany) into prefilled 
EDTA tubes on ice. After the collection process, samples 
were routinely and uniformly processed and stored in 
Nunc cryotubes (Thermo Fisher Scientific GmbH) at 
−80°C until analysis. All plasma samples underwent only 
a single freeze-thaw cycle and were analyzed in the same 
run of an immunoassay specific for the measurement 
of rodent insulin (mouse/rat insulin, Meso Scale 
Discovery, Gaithersburg, MD, USA). Results are depicted 
in Figs 1 and 2.
For the comparison of insulin single vs multiplexed 
immunoassays (Fig. 3), 38 plasma samples from mice were 
measured in duplicate and in parallel in two different 
mouse insulin assays (multiplex assay: Merck Millipore, 
Milliplex MAP Kit, Mouse Metabolic Magnetic Bead Panel, 
MMHMAG-44K; singleplex assay: Meso Scale Discovery, 
Mouse Insulin Assay, K152BZC-2). The comparison 
between the two immunoassay measurement methods 
(Passing-Bablok regression and Bland-Altman plot) has 
been carried out using the software Analyse-It (Analyse-it 
Software, Ltd., Leeds, United Kingdom, Version 4.80.2).
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